The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard...
The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The...
ESGE, Europe’s leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step...
Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx,...
13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships Paris and Boston,...
Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks...
Paris and Boston, January 14, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic...
Paris and Boston, November 20, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Paris and Boston, November 19, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT),...
Paris and Boston, November 13, 2024 – 12:15 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6...
